TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04138368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dyadic psychotherapeutic intervention
Description: Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity, using the principles of Interaction Guidance Therapy (Sameroff et al., 2004). Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: supportive intervention
Description: Supportive therapy: mothers will receive psychoeducational knowledge regarding the infants' development. The treatment will be administered one time a week during the 8-week trial period, at the subjects' home.
Study: NCT03774303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: A mobile application that will be used to prepare families for day surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: current practice
Description: the current practice used to prepare families for day surgery
Study: NCT03393208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test GIR
Description: Participants received 500 milligrams (mg) test GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test GIR
Description: Participants received 500 milligrams (mg) test GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
Study: NCT02516930

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: crowdsourced video
Description: video promoting condom use

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: social marketing video
Study: NCT02388776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROTEM
Description: A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
Study: NCT00016315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT03393208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test GIR
Description: Participants received 500 milligrams (mg) test GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test GIR
Description: Participants received 500 milligrams (mg) test GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference GIR
Description: Participants received 500 mg reference GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference GIR
Description: Participants received 500 mg reference GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference GIR
Description: Participants received 500 mg reference GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference GIR
Description: Participants received 500 mg reference GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
Study: NCT01668602

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fast Walking with Fast Functional Electrical Stimulation (FES) Training
Description: Functional electrical stimulation (FES) is a technique that causes a muscle to contract through the use of an electrical current. The therapist applies an electrical current to either the skin over the nerve, or over the bulk of the muscle, and this will cause a muscle contraction. The FES is delivered to 2 muscle groups (dorsiflexor and plantarflexor) timed appropriately with the gait cycle. FastFES gait training sessions may comprise up to six 6-minute bouts of walking with rest breaks between bouts (total 30-minutes of walking). The last training bout (bout 6) may comprise 6-minutes of over ground walking, during which subjects will be asked to walk as fast as they can. For safety, a physical therapist will walk with and guard the subject during over ground walking.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fast Walking with Fast Functional Electrical Stimulation (FES) Training
Description: Functional electrical stimulation (FES) is a technique that causes a muscle to contract through the use of an electrical current. The therapist applies an electrical current to either the skin over the nerve, or over the bulk of the muscle, and this will cause a muscle contraction. The FES is delivered to 2 muscle groups (dorsiflexor and plantarflexor) timed appropriately with the gait cycle. FastFES gait training sessions may comprise up to six 6-minute bouts of walking with rest breaks between bouts (total 30-minutes of walking). The last training bout (bout 6) may comprise 6-minutes of over ground walking, during which subjects will be asked to walk as fast as they can. For safety, a physical therapist will walk with and guard the subject during over ground walking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast Walking
Description: Fast walking training sessions will be similar to FastFES in duration, dosage, structure but no FES will be provided.
Study: NCT04062045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Hcl 0.2% Inj Vil 10Ml
Description: Group A will receive the medicine through the erector spinae catheter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: Group B will receive Saline 0,9% through the erector spinae catheter.
Study: NCT00741858

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duragen duraplasty
Description: Posterior cranial fossa repair and enlargement with application of dural patch (Duragen)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Duraguard duraplasty
Description: Posterior cranial fossa repair and enlargement with application of dural patch (Duraguard)
Study: NCT02871102

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver with PEEP and Tidal Volume Optimization
Description: A staircase recruitment maneuver will be performed on pressure control ventilation followed by a decremental PEEP trial. During the decremental PEEP trial inspiratory tidal volumes will be varied at each step between 3 ml/kg and 10 ml/kg predicted body weight while recording the continuous pressure and flow tracings from the mechanical ventilator. With each PEEP and tidal volume combination, end expiratory and end-inspiratory plateau pressure and stress index will be assessed. At the completion of the decremental PEEP trial, the patient will be returned to ARDSnet-recommended ventilator settings.
Study: NCT02603055

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30μg/0.5ml Hepatitis E vaccine
Description: three doses, 30μg/0.5ml per dose
Study: NCT00692796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Pulmonary rehabilitation is a multi-disciplinary program that includes exercise training, disease education, psychosocial education (e.g., stress management, coping with chronic illness) and nutrition education.
Study: NCT02690376

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Assisted Capsule Endoscopy
Description: Swallowed magnetic capsule for endoscopy purposes
Study: NCT00016315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT02603055

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 30μg/0.5ml Recombinant Hepatitis E vaccine
Description: 30μg/0.5ml Hepatitis E vaccine developed by Xiamen innovax biotech Co.,Ltd.,three doses, 30μg/0.5ml per dose
Study: NCT03192722

Intervention type: DEVICE
Group type: OTHER
Intervention: Colored near reading glasses
Description: Participants are provided with colored near vision glasses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colored near reading glasses
Description: Participants are provided with colored near vision glasses.

Intervention type: DEVICE
Group type: OTHER
Intervention: Lighting as determined by LuxIQ/2 or OttLite Cobra
Description: Participants are provided preferred lighting (either OttLite or lamp with findings from LuxIQ/2)

Intervention type: DEVICE
Group type: OTHER
Intervention: Lighting as determined by LuxIQ/2 or OttLite Cobra
Description: Participants are provided preferred lighting (either OttLite or lamp with findings from LuxIQ/2)
Study: NCT02431000

Intervention type: PROCEDURE
Intervention: Sperm and blood collected for analysis
Description: Sperm Collection and Freezing (Cryopreservation), Blood Collection for analysis
Study: NCT04421716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursolic Acid
Description: Ursolic Acid 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursolic Acid
Description: Ursolic Acid 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin 600mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin 600mg
Study: NCT01033877

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TdaP vaccine SSI
Description: 1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: \>= 20 I.U. tetanus toxoid (T), \>=2 I.U. diphtheria toxoid (d), 20 microgram pertussis toxoid (aP)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Td vaccine SSI
Description: 1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: \>= 20 I.U. tetanus toxoid (T), \>=2 I.U. diphtheria toxoid (d)
Study: NCT02129894

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal Binder
Description: placement of abdominal binder
Study: NCT03630471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRIDE 'Step 1' problem-solving intervention
Description: The PRIDE problem-solving intervention is one component of the PRIDE stepped care treatment architecture which comprises two sequential treatments of incremental intensity. 'Step 1' is a brief, first-line treatment. It is grounded in stress-coping theory, with a technical focus on practical problem-solving to modify developmentally salient stressors.~Step 1 has been designed as a 'low-intensity' intervention requiring fewer resources than conventional psychological treatments. This is achieved through a relatively brief delivery schedule (up to 5 x 20-30-minute sessions spread over approximately 3 weeks) and limited requirement for specialists. The delivery agents are lay counsellors receiving a combination of specialist and peer supervision. The counsellors offer guidance sessions to support the learning and implementation of problem-solving and complementary coping skills. Illustrated booklets are used to support learning of problem-solving concepts and skills practice at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: There is no established mental health service provision in the collaborating schools. The control arm participants will receive an enhancement of this 'usual care' (essentially, no care) by having access to the same illustrated booklets used in the Intervention arm, albeit without any counsellor contact.
Study: NCT00096291

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin followed by Paclitaxel
Description: Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel Paclitaxel followed by Doxorubicin
Study: NCT03611660

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Healthy Lifestyle Program
Description: Twice weekly meetings that focus on nutrition and exercise for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Healthy Lifestyle Program
Description: Twice weekly meetings that focus on nutrition and exercise for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation Instruction
Description: Participants receive six mindfulness sessions.
Study: NCT02098551

Intervention type: OTHER
Intervention: SPT and APT
Description: All patients will be tested by skin prick testing (SPT: Histamine, buffer, commercial birch pollen extract, rBet v 1 (20 and 40 μg/ml), rBet v 1 fragment 1 (20 and 40 μg/ml), rBet v 1 fragment 2 (20 and 40 μg/ml), equimolar rBet v 1 fragment mix (20 and 40 μg/ml) in duplets.~Atopy patch testing (APT: birch pollen extract, rBet v 1:160 μg/application, rBet v 1 fragment 1: 160 μg/application, rBet v 1 fragment 2: 160 μg/ml, equimolar mix of rBet v 1 fragments: 160 μg/application; negative control with vaseline alone.
Study: NCT00174668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: insulin glulisine 3 x daily (TID) subcutaneously 15 min before the start of a meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Therapy
Description: NPH (70%) plus regular insulin or insulin aspart (30%)
Study: NCT00016315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT04088630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: A single dose of 0.5 mg oral fingolimod within 24 hours of symptom onset
Study: NCT00016315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT04088630

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single oral placebo pill within 24 hours of symptom onset

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label Fingolimod
Description: A single dose of 0.5 mg fingolimod through an NGT or Dobhoff tube within 24 hours of symptom onset
Study: NCT00016315

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00201851

Intervention type: DRUG
Group type: OTHER
Intervention: Tamoxifen
Description: 20 mg po daily x 5 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg po daily x 5 years
Study: NCT04268979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eSNAP
Description: eSNAP is a web based tool that quickly collects and organizes social support information entered by Family Caregivers (FCGs) into visualizations of the size, quality, and function of support networks. Visualizations can help FCGs catalogue support resources and present them in a new way, which may make them more salient and remind FCGs of their availability.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Navigator
Description: The Caregiver Navigator will have social work training and will help Family Caregivers (FCGs) identify and leverage informal and formal social support, including enrolling or directing FCGs to services.
Study: NCT04956861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Targeted Sleep
Description: The investigators will employ an 8-week individualized targeted sleep intervention. Individualized targeted interventions have the advantage of improving adherence, reducing attrition, and making the strategy personally meaningful.
Study: NCT03779867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo acute exercise
Study: NCT00201851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 20 mg po daily x 5 years

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery: Oophorectomy
Description: Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)
Study: NCT03779867

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resting
Description: Seated resting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biomarker Analysis
Description: Correlative studies
Study: NCT00201851

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery: Oophorectomy
Description: Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)
Study: NCT03779867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00201851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery: Oophorectomy
Description: Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)
Study: NCT00677261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sciatic Nerve Block
Description: Patients randomized to Group 1 will receive a single sciatic nerve block using the infragluteal parabiceps approach, using 20 ml of 0.5 % Ropivacaine. A sham injection of the posterior capsule and fat pad using 50 cc of normal saline will be conducted at the conclusion of the surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior capsule infiltration with local anesthetic
Description: Patients randomized to Group 2 will receive a Sham sciatic nerve block using 20cc of normal saline as described above as well as extensive local anesthetic infiltration of the posterior capsule and fat pad with a solution of 50 ml of 0.2% ropivicaine.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham sciatic block and sham posterior infiltration
Description: Patients randomized to group 3 will only receive a continuous femoral nerve catheter, A sham sciatic nerve block with 20cc of normal saline as well as a sham injection of the posterior capsule and fat pad will be performed with 50cc of normal saline.
Study: NCT04276441

Intervention type: DEVICE
Intervention: Heart healthy Engagement Program with the Apple Watch Series 5 or later
Description: No drug will be given as part of this study. Participants without a diagnosis of AF will be enrolled and a heart healthy Engagement Program delivered via the Heartline app on the iPhone with the Apple Watch Series 5 or later.

Intervention type: DEVICE
Intervention: Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later
Description: No drug will be given as part of this study. Participants with a diagnosis of AF (taking a DOAC for at least 30 days) will be enrolled and an Anti-Coagulation Adherence Module delivered via the Heartline app on the iPhone with an Apple Watch Series 5 or later.
Study: NCT00174668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: 1 x daily (OD) subcutaneously at any time (but every day at the same time) according to BG
Study: NCT04302025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Participants will receive oral alectinib twice per day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Participants will receive oral entrectinib daily